ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 238 filers reported holding ACADIA PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.37 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,334,000 | -13.0% | 160,000 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $3,832,000 | +27.3% | 160,000 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $3,011,000 | +18.2% | 160,000 | 0.0% | 0.00% | +33.3% |
| Q4 2022 | $2,547,000 | -5.7% | 160,000 | -1.8% | 0.00% | 0.0% |
| Q3 2022 | $2,702,000 | +16.2% | 162,964 | -1.3% | 0.00% | 0.0% |
| Q2 2022 | $2,326,000 | -41.8% | 165,120 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $3,999,000 | +1.4% | 165,120 | -2.3% | 0.00% | 0.0% |
| Q4 2021 | $3,942,000 | +40.2% | 168,926 | -0.2% | 0.00% | +50.0% |
| Q3 2021 | $2,811,000 | -29.7% | 169,203 | +3.2% | 0.00% | -33.3% |
| Q2 2021 | $3,998,000 | -5.5% | 163,926 | 0.0% | 0.00% | -50.0% |
| Q1 2021 | $4,229,000 | -64.2% | 163,926 | -25.7% | 0.01% | -64.7% |
| Q4 2020 | $11,797,000 | +28.6% | 220,653 | -0.8% | 0.02% | +6.2% |
| Q3 2020 | $9,175,000 | -32.6% | 222,408 | -20.9% | 0.02% | -30.4% |
| Q2 2020 | $13,620,000 | +12.4% | 281,013 | -2.0% | 0.02% | -8.0% |
| Q1 2020 | $12,120,000 | +13.6% | 286,851 | +15.0% | 0.02% | +66.7% |
| Q4 2019 | $10,671,000 | +27.2% | 249,444 | +7.1% | 0.02% | +7.1% |
| Q3 2019 | $8,386,000 | -57.6% | 233,013 | -68.5% | 0.01% | +27.3% |
| Q2 2019 | $19,758,000 | +201.1% | 739,128 | +202.4% | 0.01% | 0.0% |
| Q1 2019 | $6,563,000 | +59.0% | 244,436 | -4.2% | 0.01% | +37.5% |
| Q4 2018 | $4,128,000 | +76.0% | 255,285 | +126.0% | 0.01% | +100.0% |
| Q3 2018 | $2,345,000 | +980.6% | 112,964 | +1468.9% | 0.00% | – |
| Q4 2017 | $217,000 | -92.7% | 7,200 | -90.9% | 0.00% | -100.0% |
| Q3 2017 | $2,968,000 | +84.5% | 78,810 | +36.6% | 0.01% | +66.7% |
| Q2 2017 | $1,609,000 | -31.3% | 57,685 | -15.3% | 0.00% | -25.0% |
| Q1 2017 | $2,341,000 | +19.2% | 68,100 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $1,964,000 | -9.3% | 68,100 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $2,166,000 | -55.3% | 68,100 | -54.4% | 0.00% | -20.0% |
| Q2 2016 | $4,846,000 | +150.3% | 149,300 | +115.6% | 0.01% | +25.0% |
| Q1 2016 | $1,936,000 | +155.4% | 69,250 | +225.9% | 0.00% | +100.0% |
| Q4 2015 | $758,000 | -27.9% | 21,250 | -33.2% | 0.00% | 0.0% |
| Q3 2015 | $1,052,000 | – | 31,800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |